News & Analysis as of

Weight-Loss Products Physicians

Roetzel & Andress

GLP-1 Compounding After Shortage End: What Providers Need to Know

Roetzel & Andress on

The Food and Drug Administration (FDA) recently declared an end to the shortage of semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), categorized broadly as GLP-1 weight loss medications. Both products...more

Hendershot Cowart P.C.

FDA Update: Current Guidelines for Semaglutide and Tirzepatide Compounding

Hendershot Cowart P.C. on

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP-1 medications must prepare for significant changes following the Food and Drug Administration’s...more

Hendershot Cowart P.C.

Do Cosmetic Injections Involve The Practice Of Medicine?

Cosmetic injections, such as Botox and dermal fillers, and weight-loss injections, such as Wegovy® and Ozempic®, are popular offerings at med spas, weight-loss clinics, and dermatology practices. But are they considered the...more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide